Loop Capital downgrades Alphabet, says A.I. proliferation could hurt the stock
Loop Capital analyst Rob Sanderson downgraded Google shares to hold from buy. The analyst said he believes shares have only 6% more upside from Friday’s close.
Baird says lithium stock Albemarle can surge more than 45%, cites pricing power
Baird analyst Ben Kallo upgraded Albemarle shares to outperform, citing the company’s position as a leader in the near- and longer-term.
Loop Capital says Meta’s revenue outlook is getting brighter, sees more than 35% upside for tech giant
Loop Capital upgraded Meta shares to buy from hold, citing a bullish outlook on the company’s revenue prospects.
Americans are keeping their cars longer amid sky-high prices, rising interest rates
Rising vehicle ages are good news for aftermarket parts suppliers like AutoZone, O’Reilly Automotive and Advance Auto Parts.
Raymond James says Charles Schwab can rally nearly 30% as brokerage continues to attract assets
Raymond James upgraded Charles Schwab shares to outperform. The firm’s price target implies the shares could rally more than 28% from Friday’s close.
Fanatics to buy PointsBet’s U.S. assets for about $150 million
Fanatics agrees to acquires sports betting company PointsBet’s U.S. assets for $150 million.
Justice Department secures court order blocking Trump deposition in Strzok and Page lawsuits
Justice Department secures court order blocking Trump deposition in Strzok and Page lawsuits
Airlines are offering more U.S.-Europe service than ever — but don’t expect bargains
Airlines are flying the highest number of seats between the U.S. and Europe in more than four years.
DeSantis allies could shift $86 million to help him run for president as watchdogs cry foul
Ron DeSantis, widely considered former President Donald Trump’s top potential GOP primary rival, is expected to launch his White House bid in the coming weeks.
Alzheimer’s treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
The authors said the estimated costs of Leqembi to Medicare are conservative and spending on the Alzheimer’s treatment may increase more than anticipated.
